anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PCT No. PCT/EP95/02649 Sec. 371 Date May 31, 1996 Sec. 102(e) Date May 31, 1996 PCT Filed Jul. 7, 1995 PCT Pub. No. WO96/03422 PCT Pub. Date Feb. 8, 1996The present invention provides compounds of formula (D wherein the symbol +E,uns - - -+EE  represents a single or a double bond; R is a hydrogen atom or a C1-C4 alkyl group; A is a single bond or a straight or branched C1-C6 alkylene chain; B is a straight or branched C1-C12 alkylene group optionally substituted by one or more aryl groups or fluorine atoms; W is a group R1 or (a) wherein R1 is a straight or branched C-C6 alkyl group unsubstituted or substituted by one or more fluorine atoms, provided that at least a fluorine atom is present in B or W. The compounds of the invention are useful as testosterone 5 alpha -reductase inhibitors.
There is provided herein a multivalent binding molecule and uses thereof. The molecule is useful in binding a target under certain conditions and releasing it under other conditions. The molecule has the general formula (1) of BM1-L-(BM2)n (1) wherein, BM1 is a binding moiety 1 having an affinity for site 1 on the target, BM2 is a binding moiety 2 having an affinity for a site other than site 1 on the target, n is 1 or greater, and L is a linker joining BM1 and BM2, said linker being adapted to respond to a change in its environment with a change in conformation and/or flexibility, wherein BM1 and BM2 may be the same or different and are selected such that in use each of the BM1 and BM2 existing separately has a lower binding affinity then the complex of BM1 and BM2 does when they are linked to form the molecule. BM2 may have a single binding region or multiple binding regions with affinity for the target. The binding affinity of BM1 or BM2 to the target alone is no more than 1/2 the binding affinity of the molecule of formula (1). The molecule of formula (1) can be constructed using an oligomeric or polymeric linker, such as a polypeptide sequence. Such molecules can be useful in the delayed release of drugs, in screening assays, for stabilizing enzymes such as proteases, and for controlling reactions such as blood clotting.
PURPOSE: The aim of this study was to investigate the mediating effects of health literacy on the relationship between frailty and health-related quality of life (HRQOL) among community-dwelling older adults.
METHODS: This study used the Korean Frailty and Aging Cohort Database (KFACD) for secondary data analysis. We selected data from 1,631 people without missing main variable values for analysis. Frailty was determined based on the modified Fried's phenotype [MFP], and HRQOL was measured using the Korean version of the 5-level EuroQol questionnaire (EQ-5D-5L). Health literacy was assessed using the questions on the Behavioral Risk Factor Surveillance System (BRFSS) used by the U.S. Center for Disease Control and Prevention. To examine the mediating role of health literacy in the relationship between frailty and HRQOL, Baron & Kenny's three-step mediating effect verification method was utilized.
RESULTS: The participants had a mean frailty score of 1.37±1.02, health literacy score of 8.56±2.59, and HRQOL score of 0.84±0.10. Frailty was negatively correlated with health literacy (r = -0.27, p < .001) and HRQOL (r = -0.32, p < .001), while health literacy was positively correlated with HRQOL (r = 0.34, p < .001). We observed that health literacy played a partial mediating role in the relationship between frailty and HRQOL.
CONCLUSION: To increase older adults' HRQOL, measures that directly prevent and manage frailty as well as interventions that target the enhancement of health literacy are needed.
Perfluorooctanoic acid (PFOA), a perfluoroalkyl compound, is linked to congenital heart diseases, though its underlying mechanisms remain unclear. We hypothesized that PFOA induces cardiac defects through the inhibition of the Keap1/Nrf2 pathway, leading to oxidative damage in cardiomyocytes. In this study, zebrafish embryos exposed to PFOA showed significant cardiac malformations and dysfunction, characterized by excessive reactive oxygen species (ROS), malondialdehyde (MDA) production, decreased superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GSH-Px) activities. Additionally, we observed dysregulation in the expression of key cardiac development genes (vmhc, gata4, nkx2.5, and sox9b). PFOA also reduced the expression of keap1, nrf2, and ho-1. After overexpression of Nrf2, levels of ROS and MDA decreased, while levels of SOD, CAT, and GSH-Px increased. Additionally, cardiomyocyte apoptosis and cardiac malformations were alleviated. These findings have suggested that PFOA induces oxidative stress through Keap1/Nrf2 pathway inhibition, ultimately leading to cardiac defects.
BACKGROUND: Enhanced recovery after surgery (ERAS) pathways utilize multimodal analgesia. In pathways already utilizing incisional injection of liposomal bupivacaine (ILB), we assessed the benefit of adding intrathecal opioid analgesia (ITA).
METHODS: In this randomized controlled non-inferiority trial in patients undergoing laparotomy for gynecologic malignancy, we allocated patients 1:1 to ILB alone versus ITA + ILB with 150 μg intrathecal hydromorphone. The primary endpoint was the Overall Benefit of Analgesia Score (OBAS) at 24 h following surgery. Secondary endpoints included pain scores, intravenous opioid use, and cost of care.
RESULTS: Demographic and surgical factors were balanced for 105 patients. For the primary endpoint, ILB alone was non-inferior to ITA + ILB (median OBAS at 24 h of 4 vs 4; p = 0.70). We observed a significant reduction in the need for intravenous opioids (26% vs 71%; p < 0.001) and total opioid requirements (median 7.5 vs 39.3 mg morphine equivalents, p < 0.001) in the first 24 h. Clinically relevant improvements in pain scores were identified in the first 16 h after surgery favoring ITA + ILB. Total cost of the index episode, pharmacy costs, and costs at 30 days were not statistically different.
CONCLUSIONS: Using OBAS as the primary endpoint, ILB alone was non-inferior to ITA + ILB. However, important cost-neutral benefits for ITA + ILB in the first 24 h post-operatively included lower pain scores and reduced need for intravenous opioids. These early, incremental benefits of adding ITA to ERAS bundles already utilizing ILB should be considered to optimize immediate post-operative pain.
This randomized control trial will investigate the use of a virtual reality (VR) distraction game prior to IV ketamine procedural sedation for long bone fracture reduction. Prior studies have demonstrated that children undergoing anesthesia or procedural sedation can have lingering negative behavioral changes lasting several weeks after discharge home. Children who are anxious have higher rates of developing negative behavior changes. Opiate pain control and pre-operative instructional workshops have demonstrated efficacy in decreasing negative behavior outcomes. There is some evidence that distraction techniques, such as VR, can alleviate pre-procedural anxiety and pain during procedures. To our knowledge, evaluating the use of a non-pharmacologic, virtual reality intervention and its effects on reducing post-discharge negative behavior changes following discharge from the Emergency Department has not been evaluated.
The present invention provides novel peptides of the formula X-A 6  -B 7  -C 8  -D 9  -E 10  -F 11  containing a novel (1-amino-2-hydroxy-2-heterocyclic) ethyl moiety of the formula XL 2c  at the E 10  -F 11  -position, X is a terminal group, and the remaining variables are amino acid residues. The present invention also provides novel intermediate compounds. These peptides are useful as renin inhibitors and as inhibitors of retroviral proteases. Renin inhibitors are useful for the diagnosis and control of renin-dependent hyperaldosterism, other renin-dependent cardiovascular disorders and ocular disorders. Inhibitors of retroviral proteases, such as the HIV-I protease, are useful for treating diseases caused by retroviruses, such as human acquired immunodificiency disease syndrome (AIDS). ##STR1##
BACKGROUND Small bowel obstructions (SBO) are common and can be caused by various pathologies including intra-abdominal adhesions and hernias. Less frequently, these obstructions are caused by malignancy. The following article will review the etiology and treatment of SBOs, discuss complications of hernia repair with mesh, and examine if there is an association between mesh and cancer. CASE REPORT We present the case of a man who was over 89 years old who presented with an SBO that failed non-operative management. He previously had bilateral inguinal hernia repairs with mesh and pelvic radiation for prostate cancer. Imaging obtained during the workup was concerning for malignancy. Exploratory laparotomy revealed an ascending colon adenocarcinoma and small bowel obstruction secondary to jejunal adenocarcinoma. The jejunal adenocarcinoma was adhered to and invaded into the mesh from a previous hernia repair. He underwent successful resection and anastomosis, had an uneventful postoperative course, and was discharged. Given his advanced age, he refused further workup or treatment. CONCLUSIONS The etiology and management of small bowel obstructions is multifactorial. Small bowel obstructions affect a large portion of the population worldwide and the subsequent management accounts for significant health care spending. This case shows an exceedingly rare and possibly novel case of jejunal adenocarcinoma that invaded into the hernia mesh, leading to a malignant small bowel obstruction. While there is not a clear explanation behind this patients' pathology, we hypothesize that his prior hernia surgery led to an intra-abdominal adhesion, and subsequent pelvic radiation may have facilitated the malignancy invading the mesh and causing a high-grade small bowel obstruction.
Cupric chloride injection, USP 0.4 mg/ mL is a sterile, nonpyrogenic solution intended for use as an additive to intravenous solutions for total parenteral nutrition (TPN). Each mL of solution contains 1.07 mg cupric chloride, dihydrate and 9 mg sodium chloride.

The solution contains no bacteriostat, antimicrobial agent or added buffer. The pH is 2.0 (1.5 to 2.5); product may contain hydrochloric acid and sodium hydroxide for pH adjustment. The osmolarity is 0.327 mOsmol/mL (calc.).

Cupric Chloride, USP is chemically designated cupric chloride, dihydrate (CuCl2 • 2 H2O), a crystalline compound freely soluble in water.

Sodium Chloride, USP is chemically designated NaCl, a white crystalline compound freely soluble in water.

The semi-rigid vial is fabricated from a specially formulated polyolefin. It is a copolymer of ethylene and propylene. The safety of the plastic has been confirmed by tests in animals according to USP biological standards for plastic containers. The small amount of water vapor that can pass through the plastic container wall will not significantly alter the drug concentration.
The invention relates to the field of microorganisms, and discloses a lactobacillus mucilaginosus strain with an anti-caries function and application thereof. The fermented lactobacillus mucilaginosus provided by the invention is classified as Limosilactobacillus fermentum, named WH2483 strain and deposited in the microorganism strain collection of Guangdong province on 3 months and 3 days of 2023, and the deposited number is GDMCC No. 63221. The WH 2483 strain has excellent inhibition effect on the growth of streptococcus mutans, can inhibit the formation of a streptococcus mutans biological film, and has excellent plaque generation inhibition capability. The WHH2483 strain has good copolymerization with streptococcus mutans, which makes it lose the ability to adsorb to tooth surfaces. Meanwhile, the WH2483 strain has low film forming rate, is not easy to form a biological film and has good safety on the bad influence on the tooth formation. The fermented lactobacillus mucilaginosus WHH2483 strain can obviously reduce the occurrence and deepening of dental caries induced by streptococcus mutans, and is beneficial to oral cavity and tooth health. The invention provides an application of fermented lactobacillus mucilaginosus in preparing foods, medicines or cosmetics.
The present invention provides a dermatological composition comprising a material of algae origin (e.g. Spirulina platensis) and a material of olive leaf origin, the composition comprising at least a polypeptide and hydroxytyrosol. The composition is used for treating and/or preventing skin microbial infection, such as nail fungus, tinea pedis, wound, chickenpox, and acne. The invention also provides an applicator comprising the composition. Furthermore, the present invention provides a method for preparing the skin composition. In particular, the composition comprises at least a polypeptide and hydroxytyrosol.
Patients were eligible if they had early unfavorable disease or patients who presented with stage III or IV disease .Pt assigned to receive 6 cycles of Bleomycin Etoposide, Doxorubicin, Cyclophosphamide Procarbazine, Prednisone (BEACOPP) or increased dose BEACOPP. (IDB). Patient with Stage I or II with ³4 sites of disease, age ³50, ESR³50 "B" symptoms lymphocyte depleted histology "E" site, or bulky disease were defined as early unfavorable disease and were given standard BEACOPP (SB). Those with I, II B or bulky disease or Stage III, IV were defined according the IPS. Increased dose BEACOPP (IDB) cycles of therapy was initiated only to patients with IPS of 3 or more risk factors (high risk) Standard BEACOPP (SB) cycles were initiated to those with a score of 0-2 (standard risk). All patients had baseline GA67 or hybrid PET\\CT scan at diagnosis and post first cycle for gallium scan or second cycle for hybrid PET\\CT. Upon the scan results therapy was planned and given for addition of 4 cycles. Those with negative scan received cycles of SB as of the third cycle. Dose was reduced to level I to III if patient was hospitalized due to fever and neutropenia of 5 days or longer or pt had an episode of sepsis with unstable vital signs.

Patient with residual uptake interpreted as positive scan had additional cycles of IDB for a total of 6 cycles
Nubecularia bioherms represent unique bioconstructions that are restricted to the upper Serravallian of the Paratethys and have been reported since the 19th century. They occur in the Central Paratethys in the late Sarmatian and the Eastern Paratethys in the Bessarabian both regional stages of the respective Paratethyan areas. In this study, several locations in the Vienna and Styrian basins of the Central Paratethys were studied out of which four localities were documented in detail (Wolfsthal, Maustrenk, St. Margarethen-Zollhaus, Vienna-Ruzickagasse) to reconstruct their sedimentary setting, their internal composition, and their indications of environmental parameters. The detailed studies included logging of outcrop sections, petrographic, facies and biotic analyses of polished slabs and thin sections and also cathodoluminescence analyses. These concluded that these bioconstructions are not only composed of the foraminifer Nubecularia but represent a complex mixture and interrelationships of Nubecularia, serpulids and microbial carbonate. Four boundstone types can be differentiated: Nubecularia boundstone, Nubecularia-coralline algal boundstone, stromatolitic/thrombolitic boundstone and serpulid-nubeculariid-microbial boundstone. The first 3 types are characteristic of specific localities; the fourth type occurs in all studied locations and represents the terminal association on top of the three other types. The three basal boundstones are predominantly of columnar growth form irrespective of dominance of Nubecularia, coralline algae or microbial carbonate, and the terminal boundstone is widely irregularly organized. The general depositional environment is characterized by cross-bedded oolitic grainstones with abundant quartz grains, miliolid foraminifers and mollusks. Intercalated are microbial carbonates mostly stromatolites but also thrombolites. This indicates a general high water energy environment interrupted by more calm periods when the microbial carbonate was built. The 3 basal types of bioconstructions are interpreted to reflect decreasing food supply and/or oxygenation from Nubecularia over Nubecularia-coralline algal to stromatolitic/thrombolitic boundstone. The serpulid-nubeculariid-microbial boundstone reflects an internal succession with a decrease of the same parameters. Water depth is considered very shallow ranging from 0 to a few meters, and salinity was normal marine to hypersaline. The reconstructed paleoenvironment with dominating oolite shoals and seagrass meadows was not restricted to the Central Paratethys but extended over the entire Paratethys and represented the largest oolite facies area of the entire Cenozoic!
PURPOSE: A vaccine composition for preventing north American porcine reproductive and respiratory syndrome virus is provided to effectively prevent north American porcine reproductive and respiratory syndrome virus infection. CONSTITUTION: A vaccine composition for preventing north American porcine reproductive and respiratory syndrome virus is derived from the virus(deposit number KCTC 11956BP) and contains an active ingredient by attenuating or killing the virus. The virus contains an ORF5(open reading frame) of sequence number 1 and ORF7 of sequence number 2. A method for manufacturing the composition comprises a step of subculturing the virus and a step of attenuating or killing the virus. A mutant strain of the virus is deposited as the deposit number KCTC 119757BP. The mutant strain contains ORF5 of sequence number 3 and ORF7 of sequence number 4.
Perioperative fasting remains a common clinical practice in surgical patients, aiming to prevent pulmonary aspiration during anesthesia induction, improve bowel preparation, and ameliorate the development of postoperative nausea/vomiting or other surgical-related complications. Major head-and-neck tumor excision and reconstruction surgery is one of the most time-consuming surgeries that usually takes more than 12 h to complete. In addition to the preoperative fasting and postoperative recovery time periods, most of these patients will be fasted for more than 24-36 h before they are fed via nasogastric tubes in the postoperative care units. The combination catabolic effects resulted from prolonged perioperative fasting and profound surgical stress are likely to induce extensive protein catabolism, muscle breakdown and impaired glycemic control during postoperative phase. These catabolic responses may lead to the development of post-operative surgical site infection, delayed wound healing, re-intervention, cardiac arrest, and death in diabetic and non-diabetic patients. Furthermore, prolonged gastrointestinal fasting is associated with dehydration, perturbed gut integrity/permeability (leaky gut) and microbial (bacterial) translocation that deteriorates the early recovery after reconstruction surgery. The aim of this clinical trial is to test the effect of intraoperative feeding in patients receiving head-and-neck tumor excision and reconstruction surgery, and anticipate that reduction of perioperative fasting time may improve intraoperative hemodynamics and enhance postoperative recovery due to attenuation of systemic catabolism and improvement of insulin sensitivity to glycemic control.

This single-center clinical trial will be undertaken in a randomized, double-blind, placebo-controlled fashion, in which patients with advanced head-and-neck tumor who are scheduled for extended tumor resection and free-flap reconstruction will be randomly assigned to receive control (no intraoperative feeding) or intraoperative feeding group. Feeding via the nasogastric (NG) tube will start after the establishment of tracheostomy and completion of tumor resection at fusion rate of 10-30 ml/h (feeding diet 1 Kcal/ml and 0.04 g protein/ml). This trial anticipates in detecting differences in intraoperative hemodynamic stability and development of major postoperative complications, including delayed wound healing, surgical site infections and insulin-resistant hyperglycemia between controls and intraoperative feeding group. The outcomes of this clinical trial may provide fundamental evidence for vigorous enteric nutrition and energy support during prolonged high surgical stress operation.
Venous injection of 75 IU/kg of M118 prior to percutaneous coronary intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
<P>PROBLEM TO BE SOLVED: To provide a method for treating the hair by which dye-removing properties are improved.  <P>SOLUTION: This method for treating the hair comprises a preparation step for preparing a hairdye composition by mixing a first hairdye agent and a second hairdye agent, and a dyeing step for subjecting the hair to a hairdye treatment by coating the hairdye composition on the hair and leaving the hair to be coated for a prescribed time. The method for treating the hair further has a dye-removing step for subjecting the dyed hair to a dye-removing treatment by coating a dye-removing agent composition on the dyed hair subjected to the dyeing treatment, and leaving the coated hair for a prescribed time. The hairdye composition contains at least one kind selected from a primary alcohol, an aliphatic carboxylic acid and an aromatic carboxylic acid as a component (A). The first hairdye agent contains an oxidation dye, an alkali agent, and a polymerization inhibitor as a component (B), and the second hairdye agent contains an oxidant. The dye-removing agent composition contains the component (B) as a reducing agent.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Described embodiments include a final dosage form for administering a medicament to an animal, an article of manufacture, and method. A described final dosage form includes a dosage portion having a medicament and a release element in a first medicament-release state. The medicament has a first bioavailability to the animal. The release element is modifiable ex vivo to a second medicament-release state by an exposure to a stimulus, wherein the medicament has a second bioavailability to the animal. The final dosage form includes another dosage portion having another medicament and another release element in another first medicament-release state. In the another first medicament-release state, the another medicament has another first bioavailability to the animal. The another release element is modifiable ex vivo to another second medicament-release state by an exposure to another stimulus, wherein the another medicament has another second bioavailability to the animal.